SURMOUNT-5 results, from the NEJM abstract (published July 3, 2025; read November 8, 2026)
Measure at week 72Tirzepatide (10 or 15 mg)Semaglutide (1.7 or 2.4 mg)
Mean weight change-20.2%-13.7%
Mean waist change-18.4 cm-13.0 cm
Reached 10%, 15%, 20%, 25% lossMore likelyLess likely
Most common adverse eventsGastrointestinal, mostly mild to moderate, mainly during dose escalationSame pattern

SURMOUNT-5 randomized 751 adults with obesity but without type 2 diabetes to the maximum tolerated dose of each drug, injected weekly. It was open label, meaning participants knew which drug they got, and it was funded by Eli Lilly, which makes tirzepatide.

Which works better for weight loss, semaglutide or tirzepatide?

In the one direct comparison, tirzepatide produced more weight loss on average: 20.2% versus 13.7% at 72 weeks. That 6.5-point gap is a group average, and some people on semaglutide lost more than some people on tirzepatide.

The placebo-controlled trials point the same way but cannot be compared directly. In SURMOUNT-1, tirzepatide 15 mg produced a mean 20.9% reduction at 72 weeks (treatment-regimen estimand) versus 3.1% on placebo. In STEP-1, semaglutide 2.4 mg produced 14.9% versus 2.4% at 68 weeks. Different years, sites and populations limit side-by-side reading. Higher-dose Wegovy HD (7.2 mg) was not part of SURMOUNT-5; in its own 72-week trial in the Wegovy label it averaged 18.8% versus 3.9% on placebo.

How are the two molecules different?

Semaglutide activates the GLP-1 receptor. Tirzepatide activates both the GIP and GLP-1 receptors, per the Zepbound label, which adds that nonclinical studies suggest GIP may contribute further to its effect on appetite.

Both are weekly injections that start low and step up every 4 weeks. Semaglutide is sold as Wegovy, Ozempic and Rybelsus; tirzepatide as Zepbound and Mounjaro. Semaglutide also has oral forms; tirzepatide does not. For each molecule in depth, see semaglutide and tirzepatide.

Do side effects differ?

Both cause mainly stomach and bowel side effects, especially while the dose is rising. The SURMOUNT-5 abstract reports that GI events were the most common in both groups and mostly mild to moderate; it does not give rates, and we did not read the full paper's tables.

The labels give rates from each drug's own placebo-controlled trials. On Zepbound 5 to 15 mg, nausea affected 25% to 29% versus 8% on placebo. On Wegovy 2.4 mg, nausea affected 44% versus 16% on placebo. Those numbers come from different trials with different designs, so they do not show which drug is easier to tolerate. Both carry the boxed warning for thyroid C-cell tumors in rodents.

What does each cost without insurance?

For brand-name drugs, the manufacturer self-pay prices are close at maintenance doses. For compounded versions, tirzepatide runs higher at the median.

Monthly cost comparison; Lilly terms read October 15, 2026 (1 month = 28 days); NovoCare read November 8, 2026 (pen month = 4 pens); compounded medians from first-party reads dated October 15, 2026 and NexLife November 6, 2026
OptionTirzepatideSemaglutide
Brand self-pay, starting doseZepbound KwikPen 2.5 mg: $299Wegovy pen: $199 for 2 new-patient fills, then $349
Brand self-pay, maintenanceZepbound 7.5 to 15 mg: $449 with refills within 45 days ($499 to $699 otherwise)Wegovy 1.7 or 2.4 mg: $349; Wegovy HD 7.2 mg: $399
Compounded: range of lowest all-in monthly price per program$69 to $299 (24 programs)$39 to $249 (23 programs)
Compounded: median$144$99
Example: NexLife month to month (as of Nov 6, 2026)$129$109

As arithmetic only: 12 months of compounded tirzepatide at the $144 median would be $1,728, versus $1,188 for semaglutide at the $99 median. Brand Zepbound at $449 for 11 fills, the savings card's yearly limit, comes to $4,939; 12 Wegovy 2.4 mg fills at $349 come to $4,188. Lilly's savings end December 31, 2026, and NovoCare says it will update prices after that date.

NexLife, our editorial pick, is shown as one example of a flat price at every dose. Price check, November 20, 2026 reads, month to month: for tirzepatide Eden Health charges $129, Mondae $126 and Collective $85.58 with its yearly membership; for semaglutide Mondae charges $87, Eden $99 and Collective $75.58. The price index lists every program and its conditions.

Is compounded tirzepatide or semaglutide a safe swap for the brands?

Neither is FDA-approved. Compounded tirzepatide is made with the drug in Zepbound and compounded semaglutide with the drug in Wegovy, but neither is the same product, and FDA does not review compounded drugs for safety, effectiveness or quality. FDA has warned that some semaglutide compounders use salt forms, and in September 2026 it sent Empower Pharmacy a warning letter saying its vitamin-added versions of both appeared to be essentially copies of approved products. SURMOUNT-5's results apply to the brand products tested, not to compounded versions. See compounded vs brand.

Which should you ask your prescriber about?

That depends on your health, not only the trial gap. Points worth raising: whether you have type 2 diabetes, heart disease, sleep apnea or fatty liver disease, since approved uses differ; whether you prefer a pill (only semaglutide has one); what your insurance or Medicare covers, since the Medicare GLP-1 Bridge covers Wegovy and the Zepbound KwikPen but excludes people with type 2 diabetes, sleep apnea or fatty liver disease; and how you tolerated any earlier GLP-1. Details on both brands' trial programs are on our SURMOUNT results page.

Frequently asked questions

How much more weight loss did tirzepatide produce in SURMOUNT-5?

At 72 weeks, the mean weight change was -20.2% with tirzepatide (10 or 15 mg) and -13.7% with semaglutide (1.7 or 2.4 mg), a gap of 6.5 percentage points, in 751 adults with obesity but without type 2 diabetes. Waist circumference fell 18.4 cm versus 13.0 cm. The trial was open label and funded by Eli Lilly.

Is compounded tirzepatide more expensive than compounded semaglutide?

Usually, at the median. Across our price table, the median lowest all-in monthly price was $149 for compounded tirzepatide (24 programs) and $99 for semaglutide (23 programs), on reads dated October 15, 2026, with NexLife's dated November 6, 2026. Individual programs vary widely, and low figures often depend on sales, prepaid terms or memberships.

Does tirzepatide cause more nausea than semaglutide?

The evidence we read does not settle that. SURMOUNT-5's abstract says gastrointestinal events were the most common in both groups and mostly mild to moderate, without giving rates. Each label reports nausea from its own placebo-controlled trials, about 25% to 29% on Zepbound and 44% on Wegovy 2.4 mg, but different trial designs make those numbers hard to compare.

Can I switch from semaglutide to tirzepatide?

Neither label gives a protocol for switching between the two molecules, and SURMOUNT-5 did not test switching. Both labels begin at a starting dose and step up every 4 weeks to limit stomach side effects. Whether and how to switch, and at what dose to restart, is a decision for your prescriber based on your history and tolerance.

How does NexLife's price compare with other tracked programs?

NexLife charges $129 a month for compounded tirzepatide and $109 for semaglutide month to month, prices dated November 6, 2026, the same at every dose. On November 20, 2026 reads, Mondae charged $126 and $87, Eden Health $129 and $99, and Collective $85.58 and $75.58 including its yearly membership. NexLife is our editorial pick for what it discloses, not a price ranking.

Sources

  1. Aronne LJ et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36 — published July 3, 2025; abstract read 2026-11-08 (full-text GI rates not read)
  2. Jastreboff AM et al. SURMOUNT-1. N Engl J Med 2022;387:205-216 — published July 21, 2022; abstract read 2026-11-08
  3. Wilding JPH et al. STEP 1. N Engl J Med 2021;384:989-1002 — published March 18, 2021; abstract read 2026-11-08
  4. FDA labels (DailyMed): Zepbound (revised 08/2026) and Wegovy (revised 06/2026) — adverse reaction tables and section 12.1 read 2026-11-08
  5. NovoCare: Wegovy self-pay pricing — read 2026-11-08
  6. Lilly: LillyDirect Zepbound self-pay terms — read 2026-10-15

Comparing programs? Check the all-in monthly price, the named pharmacy and the cancellation terms on the provider's own page before you pay.

Check NexLife's plans and state availability → See the price index

Researched By Dr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed By Dr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.